Premium
Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation
Author(s) -
Jaiswal Sarita Rani,
Bhakuni Prakash,
Soni Mayank,
Gupta Mahesh,
Thatai Atul,
Chakrabarti Suparno
Publication year - 2021
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13490
Subject(s) - medicine , sofosbuvir , adverse effect , transplantation , hepatitis c virus , context (archaeology) , hepatitis c , virus , immunology , gastroenterology , ribavirin , paleontology , biology
Direct Acting Antivirals (DAA) have changed the landscape of hepatitis C virus (HCV) infection with high cure rates across genotypes. However, the use of these agents in the setting of allogeneic hematopoietic cell transplantation (HCT) has been limited. In this context, we report the outcome of five children (5‐12 years) with relapsed and refractory leukemia and active HCV infection (genotype 1b), who underwent urgent haploidentical HCT and were treated with Sofosbuvir and Velpatasvir (Sof‐Vel) from initiation of treatment to 24 weeks post‐HCT. All achieved complete virologic response (VR) at a median of 2 weeks, with normalization of liver enzymes. There were no adverse events related to the use of Sof‐Vel, with no major fluctuations in cyclosporine levels. Two of the patients developed chronic GVHD and one relapsed. Sof‐Vel was continued in one of them along with sirolimus without affecting drug levels. With a median follow‐up of 15 months, four patients are disease free with sustained VR. Our study shows that combination of Sof‐Vel might be effective in inducing rapid complete and sustained VR during HCT without any major untoward drug interaction.